Roche halts lung cancer drug trial as tiragolumab fails to improve patient outcomes.
Roche halts lung cancer drug trial after experimental medicine, tiragolumab, failed to extend patients' lives or slow disease progression, even when combined with another Roche treatment and chemotherapy. The trio's results fell short of those achieved by Merck & Co.'s Keytruda and chemotherapy. Roche has experienced multiple drug-development setbacks recently, including those in Alzheimer's disease and cancer.
July 04, 2024
6 Articles